ADB-105
Hearing Loss
Pre-clinicalActive
Key Facts
About Adolore BioTherapeutics
Adolore BioTherapeutics is developing a novel neuromodulation platform centered on a proprietary gene therapy that delivers a novel CA8 therapeutic peptide directly inside targeted neurons and nerve fibers. Their lead programs target chronic osteoarthritis knee pain and the rare condition erythromelalgia, with a broader pipeline extending into epilepsy, hearing loss, and ophthalmology. The company's mission is to create safe, effective, and accessible non-opioid therapies to combat the opioid crisis by providing highly localized, disease-modifying treatments.
View full company profileTherapeutic Areas
Other Hearing Loss Drugs
| Drug | Company | Phase |
|---|---|---|
| Next-Generation Connectivity & Digital Health Features | Advanced Bionics | Development |
| Next-Gen AI Hearing Aids | Starkey | Development/Commercialization |
| Oticon Zeal™ | Oticon | Commercial Launch |
| Oticon Intent™ | Oticon | Commercial |
| Oticon Own SI™ | Oticon | Commercial |
| Oticon Jet PX | Oticon | Commercial |